Background {#Sec1}
==========

Thyroid cancer is the most common type of endocrine tumor, with an incidence that has significantly increased in the last few decades \[[@CR1], [@CR2]\]. Although well-differentiated thyroid carcinoma (WDTC) is one of the most curable of all cancers, approximately 10--20 % of patients with WDTC suffer from disease recurrence after surgery, and some eventually die from the disease \[[@CR3]--[@CR5]\]. Various risk stratification methods have been used for the proper management of patients with WDTC; however, none are completely accurate \[[@CR6]\].

Molecular biomarkers have been used as an adjunct diagnostic marker of thyroid cancer and a predictor of patient prognosis \[[@CR7], [@CR8]\]. The *BRAF* V600E mutation is the most common mutation in thyroid cancer, particularly in papillary thyroid carcinoma (PTC), and plays an important role in tumorigenesis and progression \[[@CR9]--[@CR14]\]. In Korea, PTC comprises 97.3 % of all thyroid cancers according to new data from the 2014 annual report of cancer statistics in Korea (<http://www.cancer.go.kr/>). The *BRAF* V600E mutation is highly prevalent in Korean PTC patients \[[@CR11]\]. Currently, there is controversy regarding whether the *BRAF* V600E mutation is associated with poor prognosis and aggressive clinicopathologic features in Korean PTC patients; therefore, additional prognostic biomarkers to predict a more aggressive disease are needed \[[@CR9], [@CR15]--[@CR18]\].

Somatic mutations of the promoter region of the *TERT* gene have been reported in various cancers, including thyroid cancers, but are not found in normal cells \[[@CR19]--[@CR23]\]. The frequent cytosine-to-thymine transition of the *TERT* promoter region occurs at the following positions of chr5: 1 295 228 (C228T) and 1 295 250 (C250T), which correspond to nucleotide changes -124 bp (c.-124C \> T) and -146 bp (c.-146C \> T) upstream from the ATG start site, respectively (Fig. [1](#Fig1){ref-type="fig"}) \[[@CR19]--[@CR23]\]. These *TERT* promoter mutations stimulate *TERT* transcriptional activity in cancer cells \[[@CR19]--[@CR23]\]. In thyroid cancers, *TERT* promoter mutations were predominantly found in more aggressive disease, such as tall cell variant PTC, widely invasive follicular thyroid carcinoma (FTC), poorly differentiated carcinoma, and anaplastic carcinoma \[[@CR13], [@CR18], [@CR21], [@CR24], [@CR25]\].Fig. 1Structure of the wild-type *TERT* gene and representative sequencing electropherograms of the genomic DNA of the *TERT* promoter. The g.1295228 C \> T (C228T) and g.1295250 C \> T (C250T) mutations within the *TERT* promoter gene result in a cytosine-to thymine transition at 124 bp (c.-124C \> T) and 146 bp (c.-146C \> T) upstream of the ATG start codon, respectively. g.1295228 C \> A (C228A) is a cytosine-to adenine transition at the 1 295 228 position of chr5

*ALK* gene rearrangements have recently been identified in thyroid cancer \[[@CR26]--[@CR30]\]. *EML4*, *STRN*, *TFG*, and *GTF2IRD1* have been reported as *ALK* fusion partners \[[@CR27], [@CR28], [@CR30]--[@CR32]\]. The prevalence of *ALK*-rearranged PTCs has been reported to be up to 2.2 %, although the number of study cases is limited \[[@CR26]\]. A previous study reported that *ALK* rearrangements were more frequently found in aggressive thyroid cancer, while another study found mutations only in unselected consecutive PTC cases and not in aggressive disease, such as PTCs with distant metastasis, poorly differentiated carcinomas and anaplastic carcinomas \[[@CR26], [@CR28]\].

We aimed to investigate the prevalence of *TERT* promoter and *ALK* mutations in thyroid cancer patients with a high prevalence of the *BRAF* V600E mutation and their potential contribution for the risk stratification of these patients.

Methods {#Sec2}
=======

Patients {#Sec3}
--------

We retrospectively enrolled 243 patients who underwent thyroid surgery for thyroid cancer at Seoul St. Mary's Hospital of The Catholic University of Korea with the approval of the Institutional Review Board. Informed consent was obtained from every patient. The thyroid cancers studied included 192 consecutive WDTCs without distant metastasis (consisting of 127 classic PTCs, 11 classic PTCs with tall cell features, 9 encapsulated follicular variant PTCs, 7 infiltrative follicular variant PTCs, 16 tall cell variant PTCs, 1 oncocytic PTC, 1 Warthin-like PTC, and 20 minimally invasive FTCs), 30 consecutive WDTCs with distant metastasis (consisting of 14 classic PTCs, 4 classic PTCs with tall cell features, 1 encapsulated follicular variant PTC, 1 macrofollicular variant PTC, 5 tall cell variant PTCs, 1 columnar cell variant PTC, 1 diffuse sclerosing variant PTC, 2 minimally invasive FTCs, and 1 widely invasive FTC), 7 poorly differentiated carcinomas, 5 anaplastic carcinomas, and 9 medullary carcinomas. PTC was defined as a classic type with tall cell features if it consisted of less than 50 % tall cells and as a tall cell variant if it consisted of 50 % or more tall cells \[[@CR33]\].

Mutational analyses for *BRAF* and *TERT* promoter mutations {#Sec4}
------------------------------------------------------------

Genomic DNA was isolated from manually dissected 10-μm thick paraffin-embedded tissue sections using the RecoverAll™ Total Nucleic Acid Isolation Kit (Life Technologies, Carlsbad, CA, USA). Sanger sequencing was performed to detect the presence of *BRAF* V600E and *TERT* promoter mutations. Exon 15 of the *BRAF* gene was PCR-amplified as previously reported using the following forward primer (5′-TCATAATGCTTGCTCTGATAGGA-3′) and reverse primer (5′-GGCCAAAAATTTAATCAGTGGA-3′), resulting in a 224 bp PCR product \[[@CR11], [@CR33], [@CR34]\]. A 193 bp fragment of the *TERT* promoter was amplified by PCR as previously reported using the following forward primer (5′-CACCCGTCCTGCCCCTTCACCTT-3′) and reverse primer (5′-GGCTTCCCACGTGCGCAGCAGGA-3′) \[[@CR35]\]. All *TERT* promoter mutations were confirmed using another previously reported primer set that included the following forward primer (5′-AGTGGATTCGCGGGCACAGA-3′) and reverse primer (5′-CAGCGCTGCCTGAAACTC-3′) and resulted in a 235 bp PCR product \[[@CR21]\].

Immunohistochemistry for *ALK* overexpression {#Sec5}
---------------------------------------------

Immunohistochemistry was performed on paraffin-embedded whole tissue sections of surgical specimens using the ALK antibody (clone p80, Novocastra Laboratories Ltd., Newcastle upon Tyne, UK) and the Polink-2 HRP plus anti-rabbit DAB detection kit (GBI Labs, Mukilteo, WA, USA). As a positive control, we used paraffin-embedded tissue sections from two lung adenocarcinomas with previously confirmed *ALK* rearrangement by fluorescence in situ hybridization (FISH).

FISH for *ALK* rearrangement {#Sec6}
----------------------------

We performed FISH to detect *ALK* rearrangement using a ZytoLight SPEC ALK Dual Color Break Apart Probe and Kit (ZytoVision GmbH, Bremerhaven, Germany) according to the manufacturer's protocol \[[@CR29]\]. The positive criterion for *ALK* rearrangement was defined as \> 15 % of split signal separation and/or isolated red signal in at least 100 tumor cells as previously described \[[@CR26], [@CR29]\].

Evaluation of response to radioiodine therapy {#Sec7}
---------------------------------------------

All 30 WDTC patients with distant metastasis underwent radioactive iodine (RAI) therapy. The response to RAI ablation was evaluated with a whole body iodine -131 scan, evaluation of serum thyroglobulin levels, and a computerized tomography scan. Clinical outcomes to RAI therapy were classified as complete remission (CR), partial response (PR), stable disease (SD), and progressive disease (PD) according to previously described criteria \[[@CR36]\].

Statistical analysis {#Sec8}
--------------------

The Pearson's chi-square test or Fisher's exact test was used to assess the relationship between two nominal variables. The Student's *t*-test and Mann--Whitney test were used to compare two different groups of continuous parametric or nonparametric data, respectively. For the multivariate analysis, parameters that were significant at *p* \< 0.25 in the univariate analysis were included in a multiple logistic regression test. Two-sided tests with *p* \< 0.05 were considered to be statistically significant. Statistical analysis was performed with SPSS ver. 21.0 software (SPSS Inc., Chicago, IL, USA) and SAS ver. 9.3 software (SAS Institute Inc., Cary, NC, USA).

Meta-analysis of the proportion of *TERT* promoter mutations {#Sec9}
------------------------------------------------------------

We searched the literature for *TERT* promoter mutations in thyroid cancer using PubMed and Google up to November 2015, and selected eligible articles. We then conducted a meta-analysis of the proportion of *TERT* promoter mutations according to the histologic types of thyroid cancers. Cochran Q test and I^2^ values were employed to assess statistical heterogeneity among studies. If significant heterogeneity was observed (*p* \< 0.10 or I^2^ \> 50 %), the random effect model was used for meta-analysis. Otherwise, we used a fixed-effect model for the meta-analysis. Meta-analyses were performed using done using MedCalc version 13.0.2 software (MedCalc, Ostend, Belgium).

Results {#Sec10}
=======

Prevalence of *TERT* promoter mutations, the *BRAF* V600E mutation, and *ALK* rearrangement in thyroid cancers {#Sec11}
--------------------------------------------------------------------------------------------------------------

*TERT* promoter mutations were found in 12 (40 %) of 30 WDTCs with distant metastasis, 2 (29 %) of 7 poorly differentiated carcinomas, and 3 (60 %) of 5 anaplastic carcinomas. However, no such mutations were present in the 192 WDTCs without distant metastasis or the 9 medullar carcinomas (Table [1](#Tab1){ref-type="table"}). Among *TERT* promoter mutations, the most common type was C228T (76 %), followed by C250T (18 %) and C250A (6 %) (Table [1](#Tab1){ref-type="table"}) (Fig. [1](#Fig1){ref-type="fig"}). Among 12 WDTCs with *TERT* promoter mutations, the most frequent histologic subtype was the tall cell variant of PTC (Table [1](#Tab1){ref-type="table"}).Table 1*TERT* promoter mutations, *BRAF* V600E mutation and *ALK* rearrangement in 243 Korean patients with thyroid cancerPatient*TERT* promoter mutation*BRAF* V600E*ALK* rearrangementC228TC250AC250TOverallWDTC without distant metastasis1920000142 (74 %)0 PTC, classic1270000110 (87 %)0 PTC, classic with TCF11000010 (91 %)0 PTC, EFV900001 (11 %)0 PTC, IFV700005 (71 %)0 PTC, tall cell16000015 (94 %)0 PTC, oncocytic100001 (100 %)0 PTC, Warthin-like1000000 FTC, minimally invasive20000000WDTC with distant metastasis3010 (33 %)02 (7 %)12 (40 %)15 (50 %)0 PTC, classic143 (21 %)003 (21 %)7 (50 %)0 PTC, classic with TCF42 (50 %)01 (25 %)3 (75 %)4 (100 %)0 PTC, EFV1000000 PTC, macrofollicular1000000 PTC, tall cell54 (80 %)004 (80 %)3 (60 %)0 PTC, columnar cell1001 (100 %)1 (100 %)1 (100 %)0 PTC, diffuse sclerosing1000000 FTC, minimally invasive21 (50 %)00000 FTC, widely invasive10001(100 %)00Poorly differentiated carcinoma71 (14 %)1 (14 %)02 (29 %)1 (14 %)0Anaplastic carcinoma52 (40 %)01 (20 %)3 (60 %)4 (80 %)0Medullary carcinoma9000000*WDTC* well-differentiated thyroid carcinoma, *PTC* papillary thyroid carcinoma, *TCF* tall cell features, *EFV* encapsulated follicular variant, *IFV* infiltrative follicular variant, *FTC* follicular thyroid carcinoma

The *BRAF* V600E mutation was found in 142 (83 %) of 172 PTCs without distant metastasis, 15 (56 %) of 27 PTCs with distant metastasis, 1 (14 %) of 7 poorly differentiated carcinomas and 4 (80 %) of 5 anaplastic carcinomas (Table [1](#Tab1){ref-type="table"}). However, the *BRAF* V600E mutation was not found in 23 FTCs and 9 medullary carcinomas.

None of the 243 thyroid cancers had positive ALK immunohistochemistry or ALK break apart FISH (Table [1](#Tab1){ref-type="table"}).

Relationship between *TERT* promoter mutations and clinicopathologic features of WDTCs {#Sec12}
--------------------------------------------------------------------------------------

In 222 patients with WDTC, the presence of *TERT* promoter mutations was associated with older age (*p =* 0.017), larger tumor size (*p =* 0.043), aggressive histologic subtypes (*p* \< 0.001), advanced pathologic T stage (*p* = 0.014), extrathyroidal extension (*p =* 0.035), lymph node metastasis (*p =* 0.011), lateral lymph node metastasis (*p* \< 0.001), distant metastasis (*p* \< 0.001), and advanced AJCC stage (*p* \< 0.001) (Table [2](#Tab2){ref-type="table"}). There was no association between *TERT* promoter mutations and the *BRAF* V600E mutation (Table [2](#Tab2){ref-type="table"}).Table 2Association between *TERT* promoter mutations and clinicopathologic features in 222 patients with well-differentiated thyroid carcinoma*TERT* promoter mutationsAbsent (*n* = 210)Present (*n* = 12)*p*-valueAge (mean years)45.5 ± 13.355.0 ± 11.80.017Gender Female164 (94.8 %)9 (5.2 %)0.801 Male46 (93.9 %)3 (6.1 %)Tumor size (mean mm)14.8 ± 12.531.9 ± 22.90.043Histologic types Aggressive variant^a)^18 (75.0 %)6 (25.0 %)\<0.001 Less-aggressive variant192 (97.0 %)6 (3.0 %)Pathologic T stage pT 1--297 (99.0 %)1 (1.0 %)0.014 pT 3--4113 (91.1 %)11 (8.9 %)Extrathyroidal extension Absent105 (98.1 %)2 (1.9 %)0.035 Present105 (91.3 %)10 (8.7 %)Pathologic N stage pN0105 (99.1 %)1 (0.9 %)0.011 pN1105 (91.3 %)10 (8.7 %)Lateral lymph node metastasis Absent166 (98.8 %)2 (1.2 %)\<0.001 Present43 (82.7 %)9 (17.3 %)Distant metastasis Absent192 (100 %)0\<0.001 Present18 (60.0 %)12 (40 %)AJCC stage I-II120 (100 %)0\<0.001 III-IV90 (88.2 %)12 (11.8 %)*BRAF* V600E mutation Absent62 (95.4 %)3 (4.6 %)0.738 Present148 (94.3 %)9 (5.7 %)^a)^Aggressive variant includes 21 tall cell, 1 columnar cell, and 1 diffuse sclerosing variant of papillary carcinoma and 1 widely invasive follicular carcinoma

Relationship between clinicopathologic and molecular features and distant metastases of WDTCs {#Sec13}
---------------------------------------------------------------------------------------------

The mean follow-up period of the patients with WDTC was 36.1 months. In 14 patients, distant metastases were found within 6 months of first diagnosis. Distant metastases occurred in the lung (*n* = 24), bone (*n* = 3), lung and bone (*n* = 2), and brain (*n* = 1). Distant metastasis was associated with larger tumor size (*p =* 0.001), aggressive histologic subtype (*p =* 0.003), advanced pT stage (*p* \< 0.001), extrathyroidal extension (*p =* 0.001), lymph node metastasis (*p* \< 0.001), lateral lymph node metastasis (*p* \< 0.001) and the *TERT* promoter mutation (*p* \< 0.001). However, the *BRAF* V600E mutation was inversely associated with distant metastasis (*p =* 0.007).

In the multivariate analysis, the odds ratio (OR) for distant metastasis of WDTC in patients harboring tumors with *TERT* promoter mutations and lateral lymph node metastases was 155.298 (95 % confidence interval (CI) 3.362--999.990) and 11.159 (95 % CI 1.902--65.461), respectively (Table [3](#Tab3){ref-type="table"}). The OR for distant metastases of WDTC in patients harboring tumors with the *BRAF* V600E mutation was 0.083 (95 % CI 0.021--0.327) (Table [3](#Tab3){ref-type="table"}).Table 3Multivariate analysis of factors affecting distant metastasisOdds Ratio95 % CI*p*-valueAge1.0460.999--1.0950.054Gender0.6880.197--2.4010.557Tumor size1.040.999--1.0950.083Histologic type0.8160.182--3.660.790Pathologic T stage0.1420.005--4.0160.252Extrathyroidal extension19.5350.618--617.0170.091Pathologic N stage0.9220.141--6.0530.933Lateral lymph node metastasis11.1591.902--65.4610.008*TERT* promoter mutation155.2983.362--999.9900.009*BRAF* V600E mutation0.0830.021--0.327\<0.001

Impact of molecular genotypes on response of metastatic WDTCs to RAI therapy {#Sec14}
----------------------------------------------------------------------------

Of the 30 WDTCs with distant metastasis, 9 (30 %) had coexisting *BRAF* V600E and *TERT* promoter mutations and 12 (40 %), including follicular and diffuse sclerosing variants of PTC, had no mutations (Fig. [2a](#Fig2){ref-type="fig"}).Fig. 2Molecular genotypes and radioactive iodine therapy. **a** Molecular genotypes of 30 well-differentiated thyroid carcinomas with distant metastases based on *TERT* promoter mutations and *BRAF* V600E. **b** Structural response of distant metastatic disease to radioactive iodine therapy classified by molecular genotypes in 30 well-differentiated thyroid carcinoma patients with distant metastasis. PTC, papillary thyroid carcinoma; TCF, tall cell features; FTC, follicular thyroid carcinoma; TERT, *TERT* promoter mutations; BRAF, *BRAF* V600E; (+), mutation positive; (-), mutation negative

The structural response of distant metastatic disease to RAI was evaluated at least 6 months after RAI therapy. Of the 30 WDTC patients with distant metastasis, six (20 %) patients had PR and six (20 %) had SD after RAI ablation whereas none achieved CR and 18 (60 %) had PD. There was a significant correlation between tumors with the *BRAF* V600E mutation alone and the progression of distant metastatic disease after RAI therapy (*p =* 0.025), but *TERT* promoter mutations alone were not associated with PD (Fig. [2b](#Fig2){ref-type="fig"}). PR or SD after RAI therapy was significantly more likely in patients with wild-type *BRAF* and *TERT* promoter genes (*p =* 0.024) (Fig. [2b](#Fig2){ref-type="fig"}). However, other combinations of genetic mutations were not correlated with RAI response.

Meta-analysis of *TERT* promoter mutation prevalence in thyroid cancer {#Sec15}
----------------------------------------------------------------------

Our study and 13 articles were included for the meta-analysis of *TERT* promoter mutation prevalence in various thyroid cancers \[[@CR17], [@CR18], [@CR21], [@CR24], [@CR25], [@CR32], [@CR37]--[@CR43]\]. Significant heterogeneity was found in classic PTC, FTC, Hürthle cell carcinoma, and anaplastic carcinoma among the studies (Figs. [3](#Fig3){ref-type="fig"} and [4](#Fig4){ref-type="fig"}). The mean frequencies of *TERT* promoter mutations in PTC, conventional FTC, Hürthle cell carcinoma, poorly differentiated carcinoma and anaplastic carcinoma were 11.3 % (95 % CI 9.3--13.5), 21.3 % (95 % CI 14.2--29.4), 6.7 % (95 % CI 0.2--21.4), 39.6 % (95 % CI 31.3--48.2), and 38.5 % (95 % CI 32.6--44.7), respectively (Figs. [3](#Fig3){ref-type="fig"} and [4](#Fig4){ref-type="fig"}). When PTCs were stratified by histologic subtype, mean frequencies of *TERT* promoter mutations in classic, follicular, and tall cell variants were 8.8 % (95 % CI 6.8--11.1), 6.6 % (95 % CI 4.5--9.3), 27.5 % (95 % CI 21.0--34.7), respectively (Fig. [3](#Fig3){ref-type="fig"}). *TERT* promoter mutations were not found in a total of 132 medullary carcinoma patients including our case series \[[@CR17], [@CR21], [@CR24], [@CR25], [@CR41]\].Fig. 3Forest plots of the meta-analysis for the prevalence of *TERT* promoter mutations in all papillary thyroid carcinomas (PTC), classic PTC (**b**), follicular variant of PTC (**c**), and tall cell variant of PTC (**d**). \*Only *TERT* C228T was examined. TCGA, The Cancer Genome AtlasFig. 4Forest plots of the meta-analysis for the prevalence of *TERT* promoter mutations in follicular thyroid carcinomas (**a**), Hürthle cell carcinoma (**b**), poorly differentiated carcinoma (**c**), and anaplastic carcinoma (**d**)

Discussion {#Sec16}
==========

We found that *TERT* promoter mutations are prevalent in aggressive thyroid cancers and are associated with distant metastasis of WDTCs in Korean patients with a high prevalence of the *BRAF* V600E mutation. When we examined *TERT* promoter mutations in a consecutive series of 192 WDTC patients who had no distant metastasis during the follow-up period, none carried the mutation. However, *TERT* promoter mutations were found in 40 % of WDTC patients with distant metastasis. In all 222 WDTC patients, the overall prevalence of *TERT* promoter mutations was 5.4 %. These results are lower than those reported in other countries. The prevalence of *TERT* promoter mutations reported in the literature ranged from 7.3 to 25.5 % in PTC and from 4.3 to 36.4 % in FTC \[[@CR17], [@CR18], [@CR21], [@CR24], [@CR25], [@CR32], [@CR37]--[@CR43]\].

In our study, *TERT* promoter mutations were associated with older age, larger tumors, higher stage and distant metastases in WDTCs. These findings are consistent with those of previous reports indicating that *TERT* promoter mutations are associated with aggressive clinical behavior \[[@CR21], [@CR24]\]. In the stratified meta-analysis by histologic subtype of PTC, we found that the prevalence of *TERT* promoter mutations was correlated with the degree of tumor aggressiveness. The tall cell variant of PTC exhibits more aggressive behavior than classic PTC \[[@CR27], [@CR33]\], while clinical features of the follicular variant of PTC are between classic PTC and FTC \[[@CR44]\]. The *TERT* promoter mutations were most frequently found in tall cell variant (27.5 %, 95 % CI 21.0--34.7), followed by classic PTC (8.8 %, 95 % CI 6.8--11.1) and follicular variant (6.6 %, 95 % CI 4.5--9.3). These results are consistent with findings of present study.

Many studies have shown the role of *BRAF* V600E in advanced clinical stage and distant metastasis of PTC \[[@CR7], [@CR45]\]. In contrast, we found that the *BRAF* V600E status was inversely correlated with the rate of distant metastasis in WDTCs. This contradiction may be related to case selection bias. Of 30 metastatic tumors enrolled in our study, 20 % included follicular and diffuse sclerosing variants of PTC and FTCs, which were all negative for the *BRAF* V600E mutation. It is well-known that the incidence of *BRAF* V600E is very low in the follicular and diffuse sclerosing variants of PTC, and no FTCs have the *BRAF* V600E mutation \[[@CR11], [@CR34], [@CR46]\].

In our study, the *BRAF* V600E mutation was significantly associated with low response rate of metastatic WDTCs to RAI therapy. These results are consistent with previous studies that have demonstrated high frequency of *BRAF*V600E mutation in RAI-refractory metastatic thyroid cancers \[[@CR1], [@CR47]\]. However, there was no significant effect of *TERT* promoter mutations on distant metastasis of WDTCs. The most likely mechanism of resistance to RAI therapy is the impaired iodide-handling machinery in metastatic thyroid cancer \[[@CR1]\]. Many studies have reported that *BRAF*V600E mutation reduces the expression of thyroid iodine-handling genes (sodium iodide symporter, thyroid-stimulating hormone receptor, thyroglobulin, and thyroperoxidase) in thyroid cancer \[[@CR1], [@CR47], [@CR48]\]. However, mechanism underlying the RAI therapy resistance associated with *TERT* promoter mutations remains uncertain. Xing et al reported that coexisting *BRAF* V600E and *TERT* C228T mutations defined the most aggressive subgroup of PTC when analyzed in terms of clinicopathologic features, tumor recurrence and disease-free survival rate \[[@CR18]\]. We did not observe this trend in our study (data not shown).

Two *TERT* C228T and C250T mutations create consensus binding motifs for the E-twenty-six (ETS)/ternary complex transcription factor (TCF) and increase the transcriptional activity of the *TERT* promoter \[[@CR19], [@CR23]\]. *TERT* promoter mutations in thyroid cancer and glioma were associated with increased mRNA expression and telomerase activity \[[@CR17], [@CR49]\]. *BRAF* V600E and *TERT* promoter mutations can activate the mitogen-activated protein kinase (MAPK) signaling pathway in thyroid cancer \[[@CR21]\]. In previous studies, *TERT* promoter mutations were more frequently found in *BRAF* V600E mutation-positive PTCs, suggesting an incremental and synergistic effect of the coexisting two mutations in tumorigenesis \[[@CR18], [@CR21]\]. In our study, the *TERT* promoter mutation status was not associated with the incidence of the *BRAF* V600E mutation. These discrepancies may be associated with ethnic differences given that there is a higher prevalence of the *BRAF* V600E mutation and lower occurrence of *TERT* promoter mutations in Korean patients than in Western patients. Therefore, our study results cannot be generalized to other populations.

We found no *TERT* promoter mutations in medullary carcinoma. This finding is consistent with previous reports \[[@CR21], [@CR24]\]. Moreover, *TERT* promoter mutations were not found in benign thyroid nodules, whereas they were more prevalent in poorly differentiated or anaplastic carcinomas than in WDTCs \[[@CR21], [@CR24]\]. Therefore, it is suggested that *TERT* promoter mutations are involved only in the tumorigenesis of follicular-cell derived thyroid cancers, particularly in aggressive subtypes, and may occur as a late molecular-genetic event that induces dedifferentiation of WDTCs \[[@CR21]\].

*ALK* gene rearrangements are mutually exclusive with all other known thyroid cancer driver mutations and have been reported in up to 2.2 % of PTCs, 4 % of poorly differentiated carcinomas, and 4 % of anaplastic carcinomas \[[@CR26], [@CR28], [@CR32]\]. In our study, *ALK* rearrangement was not identified in any thyroid cancers.

The main limitations of our study were the relatively small sample size of metastatic cancers and the short follow-up period. Although the analyses for disease recurrence and survival of patients were not available, we could evaluate the therapeutic response to RAI based on the distant metastatic disease genotypes. We report for the first time the clinical impact of *TERT* promoter mutations on thyroid cancers that occur in a *BRAF* V600E prevalent area.

Conclusions {#Sec17}
===========

Our study demonstrated that Korean patients have a higher *BRAF* V600E prevalence and lower prevalence of the *TERT* promoter mutation and *ALK* rearrangement in thyroid cancers than do Western patients. *TERT* promoter mutation is associated with aggressive clinicopathologic features and is a strong predictor of distant metastasis of WDTC. In Korea, the *BRAF* V600E-negative WDTCs more frequently develop distant metastasis than *BRAF* V600E-positive tumors. When WDTC patients develop distant metastases, RAI therapy is most effective in patients without *BRAF* V600E and *TERT* promoter mutations. Further prospective evaluation that includes a larger sample size is needed.
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